Delivery Order SPE2DB24D8001-SPE2DB25FKZCE
Award Date
1/24/25
Potential Completion Date
1/27/25
Potential Value
$1.4K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a pharmaceutical product, with a ceiling value of $2,133.91 and a period of performance through March 11, 2025. This contract is not set aside and is part of a larger Indefinite Delivery Contract (IDC) that Dakota Drug, Inc. holds with the DLA, identified as SPE2DB24D8001, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract has a ceiling value of $2,554.39 and is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a pharmaceutical product. The contract is a firm fixed-price delivery order and does not have a set-aside designation. This award is associated with a larger Indefinite Delivery Contract (IDC)...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract, valued at $1,106.58, is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a pharmaceutical product. The contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that Dakota Drug, Inc. holds with the DLA Troop Support Medical's ECAT...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $1,497.85 Firm Fixed Price contract is for the delivery of 4566188821 - XULANE 150-35 MCG/DAY PATCH 3S, with a period of performance through October 24, 2024. Dakota Drug, Inc. holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, which allows the company to provide a range...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $2,298.29, is for the delivery of the pharmaceutical product XULANE 150-35 MCG/DAY PATCH 3S. It is a firm fixed-price contract with a performance period extending to March 17, 2025. Dakota Drug, Inc. is a key supplier of pharmaceutical and medical products to the U.S. Department of Defense, holding a significant Indefinite...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $1,686.83, is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a pharmaceutical product. The contract has an ultimate completion date of March 25, 2025. Dakota Drug, Inc. is a key supplier of pharmaceutical and medical products to the U.S. Department of Defense, having been awarded a significant Indefinite...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The award, with a ceiling value of $2,147.04, is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S pharmaceutical products. The contract is a Firm Fixed Price Delivery Order with a period of performance through February 14, 2025. Dakota Drug, Inc. is a key supplier of pharmaceutical and medical products to the U.S. Department of Defense, holding a...
This federal contract award, identified as SPE2DB24D8002|SPE2DB25FJNJM, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a pharmaceutical product, with a ceiling value of $1,915.11 and a performance period ending on March 24, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001,...
This federal contract award, valued at $3,368.79, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a pharmaceutical product, with a performance period extending through January 16, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00. This contract,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a pharmaceutical product. The contract has a firm fixed price pricing type, a ceiling value of $3,183.12, and a period of performance through January 7, 2025. Dakota Drug, Inc. is the prime contractor and there are no major subcontractors mentioned. This contract is not associated...